70
Sylvia Wojczewski could never have imagined in her wildest dreams that she would one day produce components for genetic scissors. When she founded the company Biospring together with Hüseyin Aygün in 1997, the discovery of the CRISPR/Cas gene scissors and its potential for curing hereditary diseases “couldn’t even be imagined,” said Wojczewski on Friday in the Union Hall in Frankfurt .
The first therapy using CRISPR/Cas has now been approved, and that is also reason for Biospring to celebrate: in 2023, the company will have tripled its capacity for producing components for the genetic scissors.